Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF2BP2 | Q9Y6M1 | 1/20 | 0.56 |
| ▸ | DHODH | Q02127 | 2/20 | 0.53 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.51 |
| ▸ | ACLY | P53396 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.46 |
| ▸ | KCNK10 | P57789 | 1/20 | 0.46 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.46 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1316613 | 0.86 | SCN10A (0.49) | IGF2BP2DHODHSCN10AACLY | |
| SCHEMBL2273065 | 0.84 | MAPK1 (0.57) | DHODHACLYMEN1PKMKMT2A | |
| SCHEMBL4604141 | 0.84 | DHODH (0.48) | IGF2BP2DHODHACLYPKMHDAC2 | |
| SCHEMBL2272429 | 0.83 | IGF2BP2 (0.71) | IGF2BP2DHODHACLYMEN1PKM | |
| SCHEMBL5147436 | 0.83 | PYGL (0.54) | — | |
| SCHEMBL2276941 | 0.81 | IGF2BP2 (0.68) | IGF2BP2DHODHACLYMEN1PKM | |
| SCHEMBL2269612 | 0.81 | HDAC1 (0.53) | DHODHACLYMEN1PKMKMT2A | |
| SCHEMBL4221963 | 0.81 | DHODH (0.49) | DHODHACLY | |
| SCHEMBL2270359 | 0.80 | MEN1 (0.57) | DHODHACLYMEN1PKMKMT2A | |
| SCHEMBL2276609 | 0.79 | PKM (0.59) | DHODHACLYMEN1PKMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7999132-B2 | Anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-08-16 | — | — | US | disclosed |
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-09-24 | — | — | US | disclosed |
| EP-1820795-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | MMP13, MMP26, MMP11 | IGF2BP2 4173/4885DHODH 1469/4885SCN10A 1529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.